The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position
With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from
Related Articles
Full data on Novo Nordisk’s new amylin drug raise dosing questions
Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, raising questions about which dose Novo will…
Full data on Novo Nordisk’s new amylin drug raise dosing questions
Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, raising questions about which dose Novo will…
Off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results
An off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results, according to a new study.
GLP-1 reduced migraine frequency by nearly half, in a pilot study
Researchers say GLP-1 agonists significantly reduced migraine frequency in participants who were obese.
Senate Republicans debate Medicaid options as hospitals move to shape legislation
The Senate returns next week with critical choices on Medicaid policies that could cost hospitals billions of dollars and lead to millions losing coverage.
Nominate a 2024 STAT Wunderkind
Nominate a 2024 STAT Wunderkind STAT Wunderkinds is a chance to celebrate early-career researchers who are not yet independent scientists or program
Does the FDA commissioner’s new voucher program open a Pandora’s box?
The FDA is setting up a pilot program to review some drugs within one to two months. How fast is too fast?
How to keep yourself safe in extreme heat
Colorado is heating up fast! Joining @9news to share lifesaving tips as a dangerous heatwave hits Colorado. Don’t wait, watch this before heading outside!
Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official
The ouster of the FDA’s chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a drug review, STAT…